<?xml version='1.0' encoding='utf-8'?>
<document id="31925665"><sentence text="The real world use of combined P-glycoprotein and moderate CYP3A4 inhibitors with rivaroxaban or apixaban increases bleeding."><entity charOffset="82-93" id="DDI-PubMed.31925665.s1.e0" text="rivaroxaban" /><entity charOffset="97-105" id="DDI-PubMed.31925665.s1.e1" text="apixaban" /><pair ddi="false" e1="DDI-PubMed.31925665.s1.e0" e2="DDI-PubMed.31925665.s1.e0" /><pair ddi="false" e1="DDI-PubMed.31925665.s1.e0" e2="DDI-PubMed.31925665.s1.e1" /></sentence><sentence text="The use of direct oral anticoagulants for stroke prevention in atrial fibrillation continues to rise" /><sentence text=" Certain populations may be at higher risk for increased drug exposure and adverse events" /><sentence text=" Pharmacokinetic studies suggest increased exposure of rivaroxaban and apixaban with combined P-gp and moderate CYP3A4 inhibitors but the clinical relevance of this is unknown"><entity charOffset="55-66" id="DDI-PubMed.31925665.s4.e0" text="rivaroxaban" /><entity charOffset="71-79" id="DDI-PubMed.31925665.s4.e1" text="apixaban" /><pair ddi="false" e1="DDI-PubMed.31925665.s4.e0" e2="DDI-PubMed.31925665.s4.e0" /><pair ddi="false" e1="DDI-PubMed.31925665.s4.e0" e2="DDI-PubMed.31925665.s4.e1" /></sentence><sentence text=" This retrospective cohort study included patients receiving rivaroxaban or apixaban from January 1, 2012 to December 31, 2016 with a moderate inhibitor (amiodarone, dronedarone, diltiazem, verapamil) for at least 3 months in the drug-drug interaction (DDI) group"><entity charOffset="61-72" id="DDI-PubMed.31925665.s5.e0" text="rivaroxaban" /><entity charOffset="76-84" id="DDI-PubMed.31925665.s5.e1" text="apixaban" /><entity charOffset="154-164" id="DDI-PubMed.31925665.s5.e2" text="amiodarone" /><entity charOffset="166-177" id="DDI-PubMed.31925665.s5.e3" text="dronedarone" /><entity charOffset="179-188" id="DDI-PubMed.31925665.s5.e4" text="diltiazem" /><entity charOffset="190-199" id="DDI-PubMed.31925665.s5.e5" text="verapamil" /><pair ddi="false" e1="DDI-PubMed.31925665.s5.e0" e2="DDI-PubMed.31925665.s5.e0" /><pair ddi="false" e1="DDI-PubMed.31925665.s5.e0" e2="DDI-PubMed.31925665.s5.e1" /><pair ddi="false" e1="DDI-PubMed.31925665.s5.e0" e2="DDI-PubMed.31925665.s5.e2" /><pair ddi="false" e1="DDI-PubMed.31925665.s5.e0" e2="DDI-PubMed.31925665.s5.e3" /><pair ddi="false" e1="DDI-PubMed.31925665.s5.e0" e2="DDI-PubMed.31925665.s5.e4" /><pair ddi="false" e1="DDI-PubMed.31925665.s5.e0" e2="DDI-PubMed.31925665.s5.e5" /><pair ddi="false" e1="DDI-PubMed.31925665.s5.e1" e2="DDI-PubMed.31925665.s5.e1" /><pair ddi="false" e1="DDI-PubMed.31925665.s5.e1" e2="DDI-PubMed.31925665.s5.e2" /><pair ddi="false" e1="DDI-PubMed.31925665.s5.e1" e2="DDI-PubMed.31925665.s5.e3" /><pair ddi="false" e1="DDI-PubMed.31925665.s5.e1" e2="DDI-PubMed.31925665.s5.e4" /><pair ddi="false" e1="DDI-PubMed.31925665.s5.e1" e2="DDI-PubMed.31925665.s5.e5" /><pair ddi="false" e1="DDI-PubMed.31925665.s5.e2" e2="DDI-PubMed.31925665.s5.e2" /><pair ddi="false" e1="DDI-PubMed.31925665.s5.e2" e2="DDI-PubMed.31925665.s5.e3" /><pair ddi="false" e1="DDI-PubMed.31925665.s5.e2" e2="DDI-PubMed.31925665.s5.e4" /><pair ddi="false" e1="DDI-PubMed.31925665.s5.e2" e2="DDI-PubMed.31925665.s5.e5" /><pair ddi="false" e1="DDI-PubMed.31925665.s5.e3" e2="DDI-PubMed.31925665.s5.e3" /><pair ddi="false" e1="DDI-PubMed.31925665.s5.e3" e2="DDI-PubMed.31925665.s5.e4" /><pair ddi="false" e1="DDI-PubMed.31925665.s5.e3" e2="DDI-PubMed.31925665.s5.e5" /><pair ddi="false" e1="DDI-PubMed.31925665.s5.e4" e2="DDI-PubMed.31925665.s5.e4" /><pair ddi="false" e1="DDI-PubMed.31925665.s5.e4" e2="DDI-PubMed.31925665.s5.e5" /></sentence><sentence text=" Propensity matching was used to identify similar control patients without the presence of the DDI" /><sentence text=" The primary outcome was a time to event analysis of any bleeding episode as defined by the International Society of Thrombosis and Hemostasis" /><sentence text=" After propensity matching, 213 patients with similar baseline characteristics were included in each group" /><sentence text=" The mean CHA2DS2-VASc score was 3" /><sentence text="0 and median duration of follow-up was 1" /><sentence text="45 years" /><sentence text=" The primary outcome occurred in 26" /><sentence text="4% of patients in the DDI group and 18" /><sentence text="4% in the control group (hazard ratio 1" /><sentence text="8, 95% confidence interval [CI] 1" /><sentence text="19 to 2" /><sentence text="73; p-value = 0" /><sentence text="006)" /><sentence text=" There was no difference in bleeding rates based on type of inhibitor" /><sentence text=" Use of a combined P-gp and moderate CYP3A4 inhibitor with rivaroxaban or apixaban increased bleeding risk compared to patients without the DDI in this real world, retrospective study"><entity charOffset="59-70" id="DDI-PubMed.31925665.s20.e0" text="rivaroxaban" /><entity charOffset="74-82" id="DDI-PubMed.31925665.s20.e1" text="apixaban" /><pair ddi="false" e1="DDI-PubMed.31925665.s20.e0" e2="DDI-PubMed.31925665.s20.e0" /><pair ddi="false" e1="DDI-PubMed.31925665.s20.e0" e2="DDI-PubMed.31925665.s20.e1" /></sentence><sentence text=" Analysis in a larger patient population is needed to confirm these findings" /><sentence text="" /></document>